News & Media

MEDIAN steps up its development: new project awards and a new contract for a total of € 1.58 M

8 October 2014, Sophia Antipolis, France

Projects awarded for the management of medical images in a Phase III study for non-small cell lung cancer and in a Phase II study for bladder cancer;
Signing of a new contract with an Asian biotech company to manage imaging in a Phase II study for breast cancer.

MEDIAN Technologies (ALMDT), a leading medical imaging solutions and service provider for image interpretation and management in oncology clinical trials, cancer screening programs and routine practice in oncology, announced today that it has been selected to provide imaging solutions and services for three new studies, sponsored by leading global pharmaceutical companies and an Asian biotechnology company. These new studies represent approximately € 1.4M in project awards [*] and € 180K in signed contracts, for a total of € 1.58M.

Two of these studies are sponsored by historical clients of MEDIAN Technologies, one of which will base its Go/No Go decision for a later clinical phase on MEDIAN’s implementation of an advanced imaging biomarker. The third study is sponsored by one of the Top 10 pharmaceutical companies, now a new client for MEDIAN.

Together, these studies will involve more than 280 clinical sites across the world. Studies will start over a period running from Q4 2014 to Q4 2015.

“Through these new project awards and this new contract, our list of historical customers becomes more solid, confirming the relevance of our imaging solutions and services for clinical trials. We are particularly pleased, in this regard, that one of our historical customers, with whom we had worked in the context of their phases I and II, has now entrusted us with the management of imaging data in their phase III, demonstrating their confidence and satisfaction.” said Fredrik Brag, CEO of MEDIAN Technologies. “Moreover, we are also proud to count among our new clients a member of the top 10 global pharmaceutical companies, which adds to our existing Top 10 clients”he added.

[*] A project award notifies a company that their solution has been selected for a given project. A binding contract is then signed within the 18 months following the award, upon confirmation of the upstream clinical results.

About Median Technologies.

Median Technologies develops medical imaging software and services dedicated to oncology clinical trials, cancer screening, and clinical practice. Median Technologies standardizes and automates the interpretation of medical images in oncology to optimize the diagnosis of cancer patients and the assessment of their response to therapy. Median serves two primary markets: drug development and patient care. Median has a strategic partnership with the world’s largest CRO (Contract Research Organization) to offer integrated imaging services for clinical trials to biopharma sponsors worldwide, and a strategic partnership with Canon to develop new imaging technologies, and to address the patient care market.

Founded in 2002, Median Technologies is based in Sophia-Antipolis, France, and has a US subsidiary in Boston. Median has a global reach and actively works with clinical sites located in Asia, Europe, North and South America, and Australia.

Median has received the label “Innovative company” by the BPI and is listed on Euronext Paris’ Alternext market (ISIN: FR0011049824, ticker: ALMDT). The company is eligible for the PEA PME SME equity savings plan setup.

“We are committed to the improvement of cancer patient outcomes through innovation in medical imaging and quality execution for better screening, diagnosis, and monitoring of patients.”

Contacts

MEDIAN Technologies

Fredrik Brag
CEO
+33 4 92 90 65 82
fredrik.brag@mediantechnologies.com

Actifin (Investors)

Ghislaine Gasparetto
+33 1 56 88 11 11
ggasparetto@actifin.fr

Alizé RP (Press)

Caroline Carmagnol
Wendy Rigal

+33 1 44 54 36 66
median@alizerp.com

Cookies help us deliver our services. By using our services, you agree to our use of cookies.